A HISTORY OF IMPACT

2022

Corporate Social Responsibility

At YBL, we believe in contributing back to the society and our people. Under our CSR efforts, we adopted a village in the Talasari district in Maharashtra, India to create opportunities to earn a better livelihood, support education and better healthcare for the underprivileged.

2022

Polyclonal Antibody Production

As part of our expansion strategy, we established our Goat Farm Facility at Karjat (Maharashtra, India) in April, 2022 for the production of polyclonal antibodies. This facility has a capacity of more than 1000 goats.

2021

CDSCO Approval

We received the manufacturing license from CDSCO for our Covid-19 Diagnostic Kit that marked our entry into the RT-PCR Kit Manufacturing domain. We also developed indigenous master mix and enzymes for PCR kits. This further opens the avenues for exploring opportunities into growing area of molecular diagnostics.

2021

Launch of Integrated Drug Discovery & Development

We launched pre-clinical cancer models for end to end solutions into drug discovery development offering isogenic models for in-vitro drug testing, Biobanking services and customized solutions for drug screening and toxicology.

2021

Foray into Molecular Diagnostics

In line with the efforts by ICMR along with the Ministry of Health and Family Welfare (MoHFW) to expand and diversify testing capacity for COVID 19 detection in Indian healthcare facility and also to support the vision of “Atmanirbhar Bharat” (self-reliant India) set by India’s honourable Prime Minister Shri Narendra..Read More

2020

cGMP Expansion

We successfully launched our world-class Stem-Cell Facility to mark our entry into the Integrated Drug Discovery and Development space along with cGMP approval for our Stem-Cell facility for in-vitro models.

2019

Subsidiary Opening

As an organization we always been poised to achieve continuous growth by increasing our global footprints. In 2015, we opened our first subsidiary office in Berlin, Germany followed by subsidiary office in San Diego, USA in 2018. In 2019, we flagged off our third subsidiary office in Seoul, South Korea.

2018

Diversification into Drug Discovery & Development

Diversification of business into the arena of in-vitro research for Drug Discovery and Development was an exciting move for the organization. Since 2016, we focused extensively on innovative product and service offerings into drug discovery outsourcing space and commenced research on iPSC related models for expediting and facilitating in-vitro research.

2012

Launch of Recombinant Antigens

In 2012, the organization widened its horizon with development and manufacturing of recombinant antigens. Thereby, our product basket for in-vitro Diagnostics players globally.

2007

Launch of Monoclonal Antibodies

In 2007, we added a new feather in our cap by establishing our cell culture facility to manufacture Monoclonal Antibodies by Hybridoma method.

2007

Launch of Commercial Operations

After the initial developmental work around infrastructure in terms of manufacturing and supply chain, we started our commercial operations globally (The first commercial shipment of Carcino-Embryonic Antigen was shipped to a renowned global client in Europe).

2007

Launch of Native Antigens facility

In 2000, our first Native Antigens facility was established in Navi Mumbai, India with minimal resources and tremendous excitement and zeal. With the committed efforts of immensely talented team of scientists, we developed our portfolio of niche Native Antigens and marked our entry into the in-vitro Diagnostics space.

1999

The Dream

In 1999, a shared passion for science and research, brought three thoroughbred professionals together; Mr. Arvind Bhanushali, Mr. Bharat Dagha and Dr. Paresh Bhanushali who joined hands together and laid the foundation with a few dedicated team members. While the beginning was humble, the passion was immense and the intent..Read More